Stoke Therapeutics (STOK) Price & Analysis

Compare

447 Followers

STOK Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.35 - $24.60

Previous CloseN/A

Volume337.58K

Average Volume (3M)1.05M

Market Cap

$1.25B

Enterprise Value$418.08M

Total Cash (Recent Filing)$247.71M

Total Debt (Recent Filing)$2.30M

Price to Earnings (P/E)27.1

Beta2.05

Next Earnings

Nov 11, 2025

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding54,797,417

10 Day Avg. Volume1,120,734

30 Day Avg. Volume1,049,977

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.33

Enterprise Value/Revenue2.09

Enterprise Value/Gross Profit2.09

Enterprise Value/Ebitda9.89

Forecast

1Y Price Target

$24.88

Price Target Upside8.65% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe EMPEROR Phase 3 study began dosing subjects, with approximately 130 subjects already identified in prescreening.

Financial PerformanceSTOK reported 2Q25 total revenue $14M vs. consensus $9M, showing better than expected revenue performance.

Regulatory ProgressManagement is talking about using Zorevunersin's Breakthrough Therapy Designation to have a multidisciplinary meeting with the FDA to discuss the data to date and explore expedited access of Zorevunersen for patients.

Bears Say

Clinical RisksIf replicated in the pivotal trial, zorevunersen’s effects on Vineland-3 domains could unlock a differentiated value proposition for regulators, payors, and prescribers.

Development RisksThe tone at the company has evolved to a more aggressive stance, openly discussing the possibility of accelerated approval.

Stoke Therapeutics News

Stoke, Biogen announce data from open-label extension studies of zorevunersen

Stoke Therapeutics (STOK) and Biogen (BIIB) announced data from Phase 1/2a and open-label extension studies of zorevunersen that...

21d ago

BIIB

STOK

Biogen, Stoke presents data from Phase 1/2a, OLE studies of zorevunersen

Biogen (BIIB) and Stoke Therapeutics (STOK) announced data from Phase 1/2a and open-label extension, OLE, studies of zorevunersen...

21d ago

BIIB

STOK

Biogen, Stoke Therapeutics present data from studies of zorevunersen

Biogen Inc. (BIIB) and Stoke Therapeutics (STOK) announced presentations of new clinical data from studies of zorevunersen at...

29d ago

BIIB

STOK

Promising Potential of Stoke Therapeutics: Buy Rating Supported by Positive Zorevunersen Data and Strategic Advancements

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Stoke Therapeutics. The associated price target remains...

28d ago

STOK

Stoke Therapeutics price target lowered to $28 from $29 at BTIG

BTIG analyst Thomas Shrader lowered the firm’s price target on Stoke Therapeutics (STOK) to $28 from $29 and...

1M ago

STOK

Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating

TD Cowen analyst Yaron Werber has maintained their bullish stance on STOK stock, giving a Buy rating today....

1M ago

STOK

Promising Developments in Stoke Therapeutics’ Clinical Trials Support Buy Rating

Ananda Ghosh, an analyst from H.C. Wainwright, maintained the Buy rating on Stoke Therapeutics. The associated price target...

1M ago

STOK

Positive Outlook for Stoke Therapeutics: Promising Clinical Data and Strong Financial Position

Stoke Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer from...

1M ago

STOK

Stoke Therapeutics Advances RNA Medicine with Strong Q2 Results

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke...

1M ago

STOK

Stoke Therapeutics reports Q2 EPS (40c), consensus (54c)

Reports Q2 revenue $13.8M, consensus $5.2M. “This quarter was defined by strong execution that is driving momentum across...

1M ago

STOK

Stoke Therapeutics, Biogen announce first patient dosed in EMPEROR study

Stoke Therapeutics (STOK) and Biogen (BIIB) announced that the first patient has been dosed in the global Phase...

1M ago

BIIB

STOK

Biogen, Stoke announce first patient dosed in Phase 3 EMPEROR study

Biogen (BIIB) and Stoke Therapeutics (STOK) announced that the first patient has been dosed in the global Phase...

1M ago

BIIB

STOK

STOK Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Stoke Therapeutics (STOK) is scheduled to report 2nd quarter earnings on 08/12/2025, before the market opens. Regarding Q2...

1M ago

STOK

Stoke Therapeutics initiated with a Buy at Jefferies

Jefferies initiated coverage of Stoke Therapeutics (STOK) with a Buy rating and $30 price target The firm likes...

2M ago

STOK

STOK FAQ

What was Stoke Therapeutics Inc’s price range in the past 12 months?

Stoke Therapeutics Inc lowest stock price was $5.35 and its highest was $24.60 in the past 12 months.

What is Stoke Therapeutics Inc’s market cap?

Stoke Therapeutics Inc’s market cap is $1.25B.

When is Stoke Therapeutics Inc’s upcoming earnings report date?

Stoke Therapeutics Inc’s upcoming earnings report date is Nov 11, 2025 which is in 49 days.

How were Stoke Therapeutics Inc’s earnings last quarter?

Stoke Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.512 by $0.112.

Is Stoke Therapeutics Inc overvalued?

According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Stoke Therapeutics Inc pay dividends?

Stoke Therapeutics Inc does not currently pay dividends.

What is Stoke Therapeutics Inc’s EPS estimate?

Stoke Therapeutics Inc’s EPS estimate is -0.58.

How many shares outstanding does Stoke Therapeutics Inc have?

Stoke Therapeutics Inc has 54,797,417 shares outstanding.

What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?

Stoke Therapeutics Inc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.512. Following the earnings report the stock price went up 24.982%.

Which hedge fund is a major shareholder of Stoke Therapeutics Inc?

Currently, no hedge funds are holding shares in STOK

Stoke Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

18.17%

Trailing 12-Months

Asset Growth

24.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Stoke Therapeutics Inc

Stoke Therapeutics (STOK) is a biotechnology company focused on developing innovative RNA-based therapies to treat a range of severe genetic diseases. The company leverages its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to enhance the expression of specific genes, aiming to restore protein levels that are insufficient in certain disorders. Stoke Therapeutics primarily operates in the biotechnology sector, with a focus on rare diseases, and is advancing its lead product candidates through clinical trials to address conditions like epilepsy and other neurological disorders.

Stoke Therapeutics (STOK) Earnings & Revenues

Historic Earnings Reports

STOK Company Deck

STOK Earnings Call

Q2 2025

0:00 / 0:00

STOK Stock 12 Month Forecast

Average Price Target

$24.88

▲(8.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","36":"$36","12.75":"$12.75","20.5":"$20.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.75,20.5,28.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.91,14.60923076923077,16.30846153846154,18.00769230769231,19.706923076923076,21.40615384615385,23.105384615384615,24.804615384615385,26.503846153846155,28.203076923076924,29.902307692307694,31.601538461538464,33.300769230769234,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.91,13.830769230769231,14.75153846153846,15.672307692307692,16.59307692307692,17.513846153846153,18.434615384615384,19.355384615384615,20.276153846153846,21.196923076923078,22.11769230769231,23.03846153846154,23.959230769230768,{"y":24.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.91,13.301538461538462,13.693076923076923,14.084615384615384,14.476153846153846,14.867692307692307,15.259230769230768,15.650769230769232,16.04230769230769,16.433846153846154,16.825384615384614,17.216923076923077,17.60846153846154,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >